Company Overview

Nyxoah SA is a medical technology company focused on developing and commercializing innovative therapies for sleep-disordered breathing, primarily obstructive sleep apnea (OSA). The company operates within the medical devices and sleep medicine industries, addressing patients who are intolerant of or non-compliant with traditional continuous positive airway pressure (CPAP) therapy. Nyxoah’s core product is the Genio® System, a battery-free hypoglossal nerve stimulation device designed to treat moderate to severe OSA by stimulating airway muscles to maintain airway patency during sleep.

The company’s primary revenue driver is the development and anticipated commercialization of the Genio® System, which is positioned as a less invasive alternative to implanted neurostimulation devices. Nyxoah serves sleep clinics, hospitals, and otolaryngology specialists, with a strategic focus on patients underserved by existing therapies. Founded in 2009 and headquartered in Belgium, Nyxoah evolved from a research-driven startup into a publicly traded company, completing an initial public offering and dual listing on NASDAQ and Euronext Brussels to fund clinical development and regulatory expansion.

Business Operations

Nyxoah operates largely as a single-segment business centered on the research, development, clinical validation, and commercialization of its neurostimulation technology. Revenue generation to date has been primarily linked to limited market releases, clinical study-related activities, and preparatory commercial efforts, with broader commercialization dependent on regulatory approvals in key markets. The company maintains integrated capabilities across device design, clinical research, and physician training.

Operationally, Nyxoah conducts clinical trials and commercial activities in Europe and the United States, with manufacturing and key technology assets controlled through internal development and specialized third-party suppliers. The company collaborates with clinical research centers, sleep laboratories, and medical institutions, and operates through wholly owned subsidiaries in major jurisdictions to support regulatory, clinical, and future commercial operations.

Strategic Position & Investments

Nyxoah’s strategic direction is centered on expanding the clinical and regulatory footprint of the Genio® System, particularly through U.S. Food and Drug Administration (FDA) approval and broader European adoption. Growth initiatives include advancing pivotal clinical trials, scaling physician education programs, and preparing commercial infrastructure for large addressable markets with high OSA prevalence.

The company has historically prioritized internal research and development over acquisitions, with investments focused on clinical evidence generation, next-generation product enhancements, and intellectual property protection. Nyxoah’s strategy emphasizes differentiation through its battery-free, externally powered design, which management positions as a potential long-term advantage in patient comfort, surgical simplicity, and device longevity compared to competing implanted systems.

Geographic Footprint

Nyxoah is headquartered in Belgium and maintains an operational presence across Europe and North America. Its European activities include clinical trials, early commercial adoption, and regulatory engagement in multiple countries, while the United States represents a key strategic market due to its large diagnosed OSA population and reimbursement potential.

The company’s global footprint is supported by subsidiaries and representative offices that manage regional clinical, regulatory, and corporate functions. While commercial penetration outside Europe remains limited pending regulatory approvals, Nyxoah’s international strategy is designed to support scalable expansion across North America and selected additional markets over time.

Leadership & Governance

Nyxoah was co-founded by industry professionals with experience in medical technology and neuromodulation, and its leadership emphasizes evidence-based innovation, disciplined clinical development, and long-term value creation. Management has consistently articulated a strategic vision focused on transforming the standard of care for OSA patients who lack effective treatment options.

Key executives include:

• Olivier Taelman – Chief Executive Officer
• Chris Fitzgerald – Chief Financial Officer
• Franck Verdoodt – Chairman of the Board

Publicly available sources confirm the roles of the CEO, CFO, and Board leadership; detailed responsibilities and the full scope of other executive positions are data inconclusive based on available public sources.